Identification of Celecoxib targeted proteins using label-free thermal proteome profiling on rat hippocampus

Elham Gholizadeh[1], Reza karbalaei[2], Ali Khaleghian[1], Mona Salimi[3], Ziaurrehman Tanoli[4], Kambiz Gilany[5], Rabah Soliymani[6], Hassan Rezadoost[5], Marc Baumann[6], Mohieddin Jafari[4], and Jing Tang[7]

[1]Semnan University of Medical Sciences and Health Services
[2]Temple University
[3]Pasteur Institute of Iran
[4]University of Helsinki
[5]Shahid Beheshti University
[6]Helsingin Yliopisto Laaketieteellinen tiedekunta
[7]University of Turku

October 8, 2020

Abstract

Celecoxib or Celebrex, an NSAID (non-steroidal anti-inflammatory drug), is one of the most common medicines for treating inflammatory diseases. Recently, it has been shown that celecoxib is associated with implications in complex diseases such as Alzheimer's disease and cancer, as well as with cardiovascular risk assessment and toxicity, suggesting that celecoxib may affect multiple unknown targets. In this project, we detected targets of celecoxib within the nervous system using a label-free TPP (Thermal Proteome Profiling) method. First, proteins of the rat hippocampus were treated with multiple drug concentrations and temperatures. Next, we separated the soluble proteins from the denatured and sedimented total protein load by ultracentrifugation. Subsequently, the soluble proteins were analyzed by nano-liquid chromatography-mass spectrometry to determine the identity of the celecoxib targeted proteins based on structural changes by thermal stability variation of targeted proteins towards higher solubility in the higher temperatures. In the analysis of the soluble protein extract at 67 centigrade, 44 proteins were uniquely detected in drug-treated samples out of all 478 identified proteins at this temperature. Rab4a, one out of these 44 proteins, has previously been reported as one of the celecoxib off-targets in the rat CNS. Furthermore, we provide more molecular details through biomedical enrichment analysis to explore the potential role of all detected proteins in the biological systems. We show that the determined proteins play a role in the signaling pathways related to neurodegenerative disease - and cancer pathways. Finally, we fill out molecular supporting evidence for using celecoxib towards the drug repurposing approach by exploring drug targets.

Elham Gholizadeh[1], Reza Karbalaei[2], Ali Khaleghian[1], Mona Salimi[3], Kambiz Gilany[4], Rabah Soliymani[5], Ziaurrehman Tanoli[6], Hassan Rezadoost[7], Marc Baumann[5], Mohieddin Jafari[6*], Jing Tang[6*]

[1]Department of Biochemistry, Faculty of Medicine, Semnan University of Medical Science, Semnan, Iran. Gholizadeh.bio@gmail.com, khaleghian.ali@gmail.com

[2]Department of Psychology, College of Science and Technology, Temple University. reza.karbalaei@temple.edu

[3]Physiology and Pharmacology Department, Pasteur Institute of Iran, P.O. Box 13164, Tehran, Iran. salimi_mona@yahoo.com

[4]Avicenna Research Institute, Shahid Beheshti University, Darakeh, Tehran, Iran. k.gilany@ari.ir

[5]Medicum, Biochemistry/Developmental Biology and HiLIFE, Meilahti Clinical Proteomics Core Facility, University of Helsinki, Helsinki, Finland; rabah.soliymani@helsinki.fi , marc.baumann@helsinki.fi

[6] Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, 00270 Helsinki, Finland; mohieddin.jafari@helsinki.fi, jing.tang@helsinki.fi

[7]Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, Tehran, Iran. rezadoosthassan@gmail.com

* Correspondence:

Mohieddin Jafari,

mohieddin.jafari@helsinki.fi

Jing Tang,

jing.tang@helsinki.fi

Data Availability Statement

Data available on request from the authors

Abstract

Celecoxib or Celebrex, an NSAID (non-steroidal anti-inflammatory drug), is one of the most common medicines for treating inflammatory diseases. Recently, it has been shown that celecoxib is associated with implications in complex diseases such as Alzheimer's disease and cancer, as well as with cardiovascular risk assessment and toxicity, suggesting that celecoxib may affect multiple unknown targets. In this project, we detected targets of celecoxib within the nervous system using a label-free TPP (Thermal Proteome Profiling) method. First, proteins of the rat hippocampus were treated with multiple drug concentrations and temperatures. Next, we separated the soluble proteins from the denatured and sedimented total protein load by ultracentrifugation. Subsequently, the soluble proteins were analyzed by nano-liquid chromatography-mass spectrometry to determine the identity of the celecoxib targeted proteins based on structural changes by thermal stability variation of targeted proteins towards higher solubility in the higher temperatures. In the analysis of the soluble protein extract at 67 centigrade, 44 proteins were uniquely detected in drug-treated samples out of all 478 identified proteins at this temperature. Rab4a, one out of these 44 proteins, has previously been reported as one of the celecoxib off-targets in the rat CNS. Furthermore, we provide more molecular details through biomedical enrichment analysis to explore the potential role of all detected proteins in the biological systems. We show that the determined proteins play a role in the signaling pathways related to neurodegenerative disease - and cancer pathways. Finally, we fill out molecular supporting evidence for using celecoxib towards the drug repurposing approach by exploring drug targets.

Keywords : Celecoxib, thermal proteome profiling, rat hippocampus, proteomics, signaling network

Introduction

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Celecoxib prevents the synthesis of lipid compounds called prostaglandins, by selectively

inhibiting cyclooxygenases-2 (COX-2) [1, 2]. COX has an essential role in the synthesis of prostaglandins (PGs) derived from arachidonic acid [3]. There are two isoforms of COX: COX-1, and COX-2. COX-1, as a gastric cytoprotectant, is physiologically constitutive and responsible for renal and platelet homeostasis. COX-2, which is considered to be inductive, is arising only in situations of tissue trauma and infections [4, 5]. All types of classic NSAIDs can inhibit both COX-1 and COX-2 isoforms with a predominant effect on COX-1 [6]. Most NSAIDs have broad side effects such as bleeding, ulceration, and perforation on gastrointestinal tract, while celecoxib selectively inhibits COX-2, and does not have side effects on the digestive system [7, 8]. Since celecoxib suppresses pain and inflammation, it is one of the most commonly prescribed drugs and accounts for 5-10% of prescriptions per year [9-11]. Celecoxib can easily access the central nervous system (CNS), while the mechanism of action (MoA) through its protein targets in CNS has not yet been fully elucidated [12].

Determining the affinity of a drug for all its potential targets is the main challenge for understanding the MoA in pharmaceutical sciences. Target-based drug discovery (TDD) starts by identifying molecular targets, which are supposed to have an essential role in the disease of interest [13-15], opposed to phenotypic-based drug discovery (PDD). The mechanism of drug performance, that is essential for designing a drug, is not often considered in PDD investigations [16]. However, also TDD research has its limitations, i.e. proving the presence of a protein target in a particular biological pathway, or its involvement in disease, is a time- and cost-consuming process. Therefore, the development of alternative strategies for target deconvolution is on-demand. Some successful options are Drug Affinity Responsive Target Stability (DARTS) [17], Stability of Proteins from Rates of OXidation (SPROX) [18], CEllular Thermal Shift Assay (CETSA) [19] and Thermal Proteome Profiling (TPP) [20]. TPP, a recently suggested method, can be done in high-throughput to identify drug targets [21]. It can also be applied in living cells in addition to*in vitro* studies without requiring compound labeling. It is an approach combining CETSA and quantitative mass spectrometry, enabling monitoring of changes in protein thermal stability across heat scaling up. Identifying drug targets in TPP is based on changes in the thermal stability of proteins after their binding to the substrates, i.e. drugs [22, 23]. This stability is mostly related to the protein melting temperature (TM), a temperature in which the process of unfolding will happen [24].

Thermal stress usually causes some irreversible changes in the structure of a protein leading to unfolding. This process leads to the exposure of the hidden hydrophobic core of a protein, and finally, to its aggregation [25, 26]. For proteins connected to a ligand (e.g. a drug), more energy is needed for unfolding because the dissociation of a ligand from the protein requires some energy itself [22]. In other words, binding of a ligand to a protein causes the formation of a complex with increased stability compared to the free protein. Therefore, these proteins are more resistant to the process of unfolding induced by heat, a fact that is the basis of TPP [20, 27-29]. TPP can be used to investigate any change in the structure of the protein [27]. TPP is unique in having the following advantages: While not requiring any labeling, it can be applied to living cells, and it permits an objective search of drug targets [30].

In the present study we have investigated targets of celecoxib, a high prevalence drug, using a label-free TPP method in rat hippocampus. We also provide supporting computational evidence related to biological annotations of the targets to explain the potential repurposing implications of this NSAID [31, 32]. We further show that several proteins related to cancer and inflammation pathways are the targets of Celecoxib. The results of these experiments are also compared with the available knowledge across all drug-target interaction databases. In addition to reinforcing previous findings, we especially explore more potential off-targets of Celecoxib within the nervous system. Based on these results we suggest a conceivable repurposing strategy of this drug for neuronal inflammation as well as cancer.

Materials and Methods

Preparation rat brain for protein extraction

Five rats were used as biological replicates, considering not affecting the present study by two crucial variables (i.e., gender and weight). Therefore, five male rats of *Rattus norvegicus* were prepared by the weight of 200+_10 gr. After dissecting the hippocampus under complete anesthesia, tissue was washed two times with cold PBS. Experiments were approved by the local Animal Ethics Committee (National Institute for Medical Research Development Ethics Board, NIMAD, No.964580). Immediately after washing, the hippocampus was homogenized and lysed in RIPA buffer. Then, the homogenates were centrifuged at 20,000 g for 20 min at 4°C in order to separate the protein extracts from precipitates [33]. Bradford assay was used to measure protein concentrations.

Drug treatment and heating procedure

A solution of celecoxib in dimethyl sulfoxide (DMSO) was added to the protein extracts to have a 0.1% final DMSO concentration. In this study, five concentrations of celecoxib including 20 µM, 10 µM, 5 µM, 1 µM and 0.1µM, were used, based on the pharmaceutical implications as described previously [34-37]. Two negative controls, i.e., control with DMSO and control with pure DD water were also used. The starting protein amounts in each tube were 1600 µg in total of 400 µl solution. The extracts were incubated for 10 min at 23°C, and then divided into four aliquots of 100 ml.

These 4 aliquots were heated at the following temperatures: 37°C, 47 °C, 57 °C, and 67 °C for 3 min. This was followed by cooling down at room temperature for 3 minutes. Subsequently, the extracts were centrifuged at 60,000 g for 30 min at 4°C and finally, the supernatant which contained soluble targeted proteins was collected and stored at -20°C for further investigations as previously described [20, 38].

Sample preparation, proteolytic digestion, and nano LC-ESI-MS/MS

Next, the extracted proteins treated with the highest drug concentration, i.e., 20 µM at the highest temperature, i.e., 67°C was selected for the protein identification step. The highest dosage of Celecoxib and the highest temperature was used not to detect the weak or transient interactions of Celecoxib and the proteins. The same temperature was used to analyze and identify proteins in the control negative samples.

The protein samples were digested in Amicon Ultra-0.5 centrifugal filters using a modified FASP method [39, 40]. In brief, reduction and alkylation of samples were performed by the addition of tris (2-carboxyethyl) phosphine (TCEP) and iodoacetamide to a final concentration of 2 mM and 50 mM respectively and incubation in the dark for 30 min. The trypsin solution was added in a ratio of 1:50 w/w in 50 mM ammonium bicarbonate and incubate overnight at room temperature. The peptide samples were cleaned using C18-reverse-phase ZipTipTM (Millipore). Dried peptide digest was re-suspended in 1% TFA, and sonicated in a water bath for 1 min before injection. Fractionated protein digests were analyzed in nano-LC-Thermo Q Exactive Plus Orbi-Trap MS. Each sample run was followed by two empty runs to wash out any remaining peptides from previous runs. The peptides were separated by Easy-nLC system (Thermo Scientific) equipped with a reverse-phase trapping column Acclaim PepMapTM 100 (C18, 75 µm × 20 mm, 3 µm particles, 100 Å; Thermo Scientific), followed by an analytical Acclaim PepMapTM 100 RSLC reversed-phase column (C18, 75 µm × 250 mm, 2 µm particles, 100 Å; Thermo Scientific). The injected sample analytes were trapped at a flow rate of 2 µl min-1 in 100% of solution A (0.1 % formic acid). After trapping, the peptides were separated with a linear gradient of 120 min comprising 96 min from 3% to 30% of solution B (0.1% formic acid/80% acetonitrile), 7 min from 30% to 40% of solution B, and 4 min from 40% to 95% of solution B.

LCMS data acquisition was done with the mass spectrometer settings as follows: The resolution was set to 140,000 for MS scans, and 17,500 for the MS/MS scans. Full MS was acquired from 350 to 1400 m/z, and the 10 most abundant precursor ions were selected for fragmentation with 30 s dynamic exclusion time. Ions with 2+, 3+, and 4+ charge were selected for MS/MS analysis. Secondary ions were isolated with a window of 1.2 m/z. The MS AGC target was set to 3 x 106 counts, whereas the MS/MS AGC target was set to 1 x

105. Dynamic exclusion was set with a duration of 20 s. The NCE collision energy stepped was set to 28 kJ mol^{-1}.

Proteomic data and bioinformatic analysis

Following LC-MS/MS acquisition, the raw files were qualitatively analyzed by Proteome Discoverer (PD), version 2.4.0.305 (Thermo Scientific, USA). The identification of proteins by PD was performed against the UniProt Rat protein database (release 11-2019 with 8086 entries) using the built-in SEQUEST HT engine. The following parameters were used: 10 ppm and 0.25 Da were tolerance values set for MS and MS/MS, respectively. Trypsin was used as the digesting enzyme, and two missed cleavages were allowed. The carbamidomethylation of cysteines was set as a fixed modification, while the oxidation of methionine and deamidation of asparagine and glutamine were set as variable modifications. The false discovery rate was set to less than 0.01 and a minimum length of six amino acids (one peptide per protein) was required for each peptide hit.

Following the identification of proteins, for better understanding of the role and importance of proteins, enrichment analysis was used to determine the corresponding biological processes by EnrichR [41]. Eight different libraries were selected to explore biomedical annotations of drug targets, including gene ontology (GO), molecular function (MF), GO Cellular Component (CC), GO Biological Process (BP), DisGeNet [42], HumanPhen [43], Mouse Genome Informatics (MGI) [44], PheWeb [45] and WikiPathways [46]. We used Enrichr's combined scores and adjusted p-values to sort annotations descendingly. Also, PEIMAN software was used to determine possible enriched post-translational modifications (PTM) in the list of protein targets [47].



Figure 1. Schematic representation of TPP-based drug target discovery using samples of rat

hippocampus. Then, we extract proteins from the hippocampus following tissue homogenization and cell lysis. Next, the samples were treated with a range of compound concentrations. Each concentration was treated with four serial temperatures, i.e., 37C, 47C, 57C, 67C. Then, soluble proteins were separated and tryptic digested before Mass spectrometry. Protein identification was made using nano LC-ESI-Thermo Q Exactive Plus Orbi-Trap MS followed by Proteome Discoverer software. Finally, data processing and computational analysis were performed to compare with previously identified celecoxib targets in different databases, and to explore the possible enriched biological annotations in the identified protein targets.

Result

The amount of soluble proteins significantly decreased with increasing temperature (Supplementary Figure 1). The declining pattern was observed for all the five drug concentrations; 20μM, 10 μM, 5 μM, 1 μM, 0.1 μM, and two negative controls, i.e., water and DMSO. Finally, the protein sample treated in 20 μM drug concentration and 67 was chosen for further analysis. In fact, proteins start unfolding at high temperature unless the binding energy of any binding partner such as a drug is high enough [48, 49]. We used the highest temperature to avoid detecting the weak and transient interactions among Celecoxib and the proteins. Also, we selected the highest dosage of Celecoxib to detect all potent drug-target interactions.









Φιγυρε 2. (Α) Τηε ἔνν διαγραμ οφ ιδεντιφιεδ προτεινς οφ ρατ ηιπποςαμπυς προτεομε, ρεςοερεδ βψ ΤΠΠ τεςηνιχυε ιν 3 γρουπς: τρεατεδ ωιτη ΔΜΣΟ, Η2Ο, ἔλεςοξιβ (20μΜ). (Β) Δρυγ-ταργετ δαταβασε ςομπαρισον βασεδ ον ςελεςοξιβ-ταργετεδ προτεινς ωιτηιν διερσε σπεςιες. Ιν τηις ινσετ πλοτ, ιντερσεςτιονς βετωεεν τηε δαταβασες αρε ιλλυστρατεδ. Τηε ηοριζονταλ βαρ πλοτ σηοως τηε τοταλ νυμβερ οφ προτεινς ιν εαςη δαταβασε. Τηε ερτιςαλ βαρ πλοτ ινδιςατες τηε νυμβερ οφ προτεινς ιν εαςη δαταβασε υνιχυελψ ανδ τηε διφφερεντ σετς οφ τηε ιντερσεςτιονς. Δρυγ Βανκ (ΔΒ), Συπερ Ταργετ (ΣΤ), Δρυγ ἔντραλ (Δ˚), Προβες & Δρυγς πορταλ (ΠΔΠ), Δρυγ Ταργετ ὄμμονς (ΔΤ˚) αρε ρεπρεσεντεδ ιν τηις πλοτ. Τηε ινσετ πλοτ δισπλαψς τηε ςηαραςτεριζεδ σπεςιες ιν τηε μεντιονεδ δαταβασες. Ωε σςαλεδ τηε ωορδ σιζε βψ τηειρ φρεχυενςψ οφ ςορρεσπονδινγ προτειν ταργετς οφ ςελεςοξιβ ιν εαςη σπεςιες ινδεπενδεντλψ. (˚) Ρατ-σπεςιφις δρυγ-ταργετ δαταβασες ςομπαρισον βασεδ ον ςελεςοξιβ-ταργετεδ προτεινς αλονγ ωιτη τηε ΤΠΠ-ιδεντιφιεδ προτεινς (Δ) Ηομολογψ νετωορκ οφ ΤΠΠ-ιδεντιφιεδ προτεινς ανδ ρεπορτεδ ταργετς οφ ςελεςοξιβ ιν δρυγ-ταργετ δαταβασες. Τηε ιδεντιφιεδ προτεινς ιν τηε πρεσεντ στυδψ αρε σηοων ωιτη α ρεδ τριανγλε, ανδ τηε προτεινς ιντροδυςεδ βψ τηε δαταβασες αρε δισπλαψεδ ωιτη γρεεν ςιρςλες. Τηε τηιςκνεσς οφ τηε εδγες ινδιςατες τηε ιδεντιτψ περςενταγε οφ προτειν σεχυενςες ιν τηις στυδψ.

A comprehensive comparison of identified proteins in samples treated with celecoxib and two controls is shown in Fig. 2A. These proteins were soluble at 67°C, following the treatment in 20μM celecoxib, water,

and DMSO, respectively, and finally detected by nano-LC-Thermo Q Exactive Plus Orbi-Trap MS. Water control treatment contains only protein samples without any other additional substances, and 351 proteins are detected in this subset. Also, 378 proteins were identified in the DMSO treatment (other negative control). Furthermore, 357 proteins were detected in the drug-treated sample, in which 44 proteins were specific to this subset. Fifteen out of all identified proteins are heat shock proteins (HSP), which indicate the intrinsic structural stability of these proteins across the high temperature [50]. The identified HSPs were shared with other groups, such as Heat shock protein HSP 90-beta and 60 kDa mitochondrial heat shock protein. Thus, we could infer that HSPs are not the particular targets of celecoxib.

We also examined the previously known targets of celecoxib according to five drug-target databases for all species (Fig. 2B) including*Rattus norvegicus* (rat) in particular (Fig. 2C). Then, we compared the TPP-identified proteins with the known targets of this drug in rats. Out of 242 already identified celecoxib targets for 24 species in all five databases, only 21 proteins are found in rat. Figure 2B-C shows the total number of proteins in each set by the horizontal bar plots. The vertical bar plot indicates the number of proteins in each database uniquely and the different set of the intersections, sorted by the frequency of targets. In this analysis, we selected five well-known drug-target databases, i.e., Drug Bank (DB) [51], Super Target (ST) [52], Probes & Drugs portal (PDP) [53], Chembl [54], and Drug Target Commons (DTC) [55, 56]. The DB database shows five targets for celecoxib of which one was related to the rat. The ST database and PDP suggests 41 and 45 proteins as a target of celecoxib of which three and five are expressed in the rat, respectively. Searching in DTC and Chembl databases, introduced 168 and 203 proteins in 24 species as a Celecoxib target and 17, and 16 of them are specified in the rat, respectively. In total, around 70% of the identified targets are related to human proteins and the proportion of rat-specific proteins is much lower, especially if we consider each database independently. It can imply the lack of complete information in rat species databases, avoiding a more comprehensive celecoxib target profile in rats. It should be considered that most of the introduced protein targets are associated with the COX protein family, and are involved in NSAID related pathways, i.e., inflammatory process, which is the explicit indication of this drug.

As shown in Figure 2B, the intersection of all databases contains only two human proteins, i.e., PDPK1, CA2 and one rat protein, Ptgs2, due to the cross-reference of the resources. Chembl and DTC are the most comprehensive drug target bioactivity resources based on manual curation (more than 1.9 million chemicals and 13,000 protein targets); therefore, it was expected that they have the highest number of intersected proteins for Celecoxib. At the same time the other databases used experimental evidence to explore targets of drugs. Only six proteins have been identified as Celecoxib targets using ST, DB, and PDP so far. On the other hand, the main subject of celecoxib studies is to study the effects of this drug on the heart and circulatory system; hence researchers focused on exploring new off-targets on related organs and tissues. Although Celecoxib can simply pass through the blood-brain barrier (BBB), its impacts on the brain and CNS have not been well described. Here, we focused on a minute part of CNS, i.e., the hippocampus; hence we did not anticipate to observe a high proportion of intersected protein targets with the other databases. However, we found a Ras-related protein Rab-2A as a shared celecoxib targeted protein between TPP-identified proteins and the PDP database. The high amount of expression of Rab-2A in the whole brain has been previously reported [57], which was helpful for our study (Fig. 2-supplementary Figure 2). This protein can be a clue to explain the association of Celecoxib with cancer-related pathways since Rab-2A is a cancer driver gene product, and it plays a role in promoting tumorigenesis [58].

We also investigated the homology of TPP-identified proteins with reported Celecoxib targets to explore structural similarities (Fig. 2D). The overall similarity of amino acid sequences in both protein groups was represented using a protein homology network. In this graph, the thickness of the edges indicates the amino acid identity percentages. There is a 665 and 3138 pairwise similarity with more than 25% and 10% thresholds. Thus, it can be concluded that several of TPP-identified proteins have a close homology with the previously reported celecoxib targeted proteins.

Furthermore, to characterize the related biological functions of the TPP-identified proteins, we implemented gene enrichment analysis using disease and pathway-related resources available in Enrichr (Fig. 3). The

enriched annotations in DisGeNet database include muscular stiffness with the lowest adjusted p-value. Neurodegenerative diseases such as Alzheimer's disease and epilepsy and breast cancer-related annotations are also highly enriched in these proteins. Therefore, it can be a clue for celecoxib to be a potential choice for add-on therapy in these diseases. We also assessed other resources such as MGI, HumanPhen, and PheWeb for exploring enriched phenotypic annotations in the TPP-identified list of 44 proteins. In these databases, terms such as Broad head, increased motor neuron number, Schizophrenia, psychotic disorders, acquired hemolytic anemias, and abnormal thrombopoiesis showed the lowest adjusted p-value. In the perspective of pathway enrichment analysis, mRNA processing, such as cytoplasmic ribosomal proteins and splicing factor Nova regulated synaptic proteins, were also enriched along with cancer-related pathways such as IL-3, PIK3-Akt-mTOR and G protein-mediated signaling pathways which have an importance in cancer, inflammation, and neurodegenerative diseases.



Figure 3. Enrichment analysis of TPP-identified proteins as the targets of celecoxib in the rat hippocampus. This plot indicates enriched annotations related to disease, phenotypes, and biological pathways of celecoxib targeted proteins. Each panel distinctly represents the annotations of gene-disease associations (DisGeNET), Human Phenotype Ontology (HumanPhen), Mouse Genome Informatics (MGI), UKBiobank PheWeb, and WikiPathway.

In Figure 4, the enriched gene ontology annotations i.e., biological processes (BP), cellular components (CC), and molecular functions (MF) were summarized by using semantic similarity. The annotations of BP were divided into six major subsets (Fig. 4A). The SRP-dependent co-translational protein, targeting to membrane processes, contributes to the prominent concept in this analysis. This process is responsible for the targeting of proteins to the cell membrane during translation, and it is dependent on two key components, the signal-recognition particle (SRP) and the SRP receptor. Rab protein signal transduction is the second most prevalent annotation in the tree-map of BPs. Rab proteins represent the largest branch of the Ras-like small GTPase superfamily, alternating between GTP- and GDP-bound states and releasing a series of molecular signals within the cell. Nuclear-transcribed mRNA catabolism, nonsense-mediated decay, post-translational protein modification, and neutrophil-mediated immunity are four other groups of annotations in BP similar to the result of pathway enrichment analysis. These terms indicate the long-term effects of Celecoxib by PTM-related mechanisms and G protein-related signaling pathways. At the molecular level, nine groups of MF annotations were illustrated for TPP-identified proteins (Fig. 4B). The activities related to signal

transduction in neuronal cells involving transport mechanisms were also highlighted, such as myosin, actin, and cadherin binding, in addition to GDP binding and GTPase activity. The enriched annotations of CC are mainly corresponding to the cytosolic part, which also underscores altering the signaling pathways [59] (Fig. 4C).







Figure 4. REVIGO Gene Ontology treemaps for TPP-identified proteins as the targets of celecoxib in the rat hippocampus. Each rectangle is a single cluster representative of enriched annotations. The loosely related annotations are joined together and visualized with different colors. The size of the rectangles was adjusted to reflect the frequency of the GO annotations in the (A) BP, (B) MF, and (C) CC.

The enriched PTMs in TPP-identified proteins were also evaluated by PEIMAN software. It is presumed that soluble proteins at 67C might be enriched in any of PTMs to last longer under temperature changes. We observed fifteen enriched PTMs, which emphasizes the role of PTMs in the thermostability of proteins. For example, Acetylation, prenylation, and phosphorylation are significantly detected in all TPP-identified proteins. Citrullination was the specific PTM for Celecoxib targets which was statistically enriched by adjusted p-value 7.6E-3. All of the enriched PTMs were confirmed by re-searching the proteomic data using these PTM as variable modifications in Proteome Discoverer.



Figure 5. Enriched PTMs in Celecoxib-treated and untreated samples. The PTMs of

Celecoxib- targets were shown by triangle and others by circle.

Discussion

Celecoxib is one of the top-selling NSAID medicines in the world [60]. Also, NSAIDs involve 5%-10% of the remedy of all prescriptions per year [37, 61]. There are some reports that show the possible indication of celecoxib with the neurodegenerative diseases associated with inflammatory processes [62-66]. Though celecoxib can pass through the BBB and access to the CNS, reports about side effects of celecoxib [67, 68] are related to cardiovascular diseases rather than the nervous system [12]. In other words, the major molecular footprints of this medicine on central nervous system (CNS) are not well-described [12]. Indeed, as we expected, we observed that most of the introduced targets of celecoxib in different databases are not related to CNS. Considering the essential role of celecoxib in the treatment of pain and inflammation, and its influence on the CNS, our study aimed to characterize protein targets of this drug especially in the nervous system.

One of the identified celecoxib-targets is Rab-2A, which is a GTPase required for protein transport from the endoplasmic reticulum to the Golgi complex by regulating COPI-dependent vesicular transport [69, 70]. This protein was common between TPP-identified targets and the PDP database (Fig. 2C). PDP is a powerful up-to-date web resource that unifies various commercial and public bioactive compound libraries [53]. To explore the role of Rab2A in detail, Sugawara *et al.*studied the effect of Rab2A knockdown on glucose-stimulated insulin secretion and the Golgi intermediate compartment in the corresponding cells. They reported that inactivation of Rab2A mitigated glucose-induced ER stress and inhibited apoptosis induced by ER stress through enlarging of the endoplasmic reticulum (ER)-Golgi intermediate compartment [71]. Therefore, it seems that celecoxib is associated with apoptosis by targeting Rab-2A and implicating ER stress. Providing more evidence through testing celecoxib on the same cells, insulinoma cells, to clarify the celecoxib influence on the ER stress is warranted.

Also, TPP-identified proteins were enriched in pathways related to neurodegenerative disease and cancer. Interestingly, the anticancer activity of celecoxib has been reported in various models of animal tumors, and it is proposed that this drug is beneficial for the prevention and treatment of cancer [72-74]. The molecular mechanisms of antitumoral effects of celecoxib have become a challenging issue, since some reports showed that the effect of celecoxib on cancer is apart from COX-2 inhibition, meaning that celecoxib has other targets than COX-2 [2, 75, 76]. Several components as intermediate candidates have been proposed for the anticancer effects of celecoxib, the most common of which is the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) [1, 77, 78]. Our CC enrichment analysis also disclosed that the endoplasmic reticulum lumen annotation was statistically enriched in TPP-identified proteins, such that several of the proteins involved in the pathways that regulate calcium concentrations, including ERO1A, ARSB, NOL3, STIM1, CALCR, SDF4, and BAX (Figure 4). Interestingly, it has been previously shown that celecoxib increases the intracellular concentration of calcium by inhibiting SERCA [1, 77-79] and the long-term leakage of calcium from the endoplasmic reticulum acts as a potent stimulant of ER stress, which finally leads to cell death and exerts its effect on cancer [77, 80].

Several members of the Ras-associated binding (Rab) family are obviously expressed in various cancer tissues, and dysregulation of Rab expression could be tumorigenic or tumor-suppressive [81]. The Rab family plays an essential role in multiple aspects of membrane trafficking control. Therefore, vesicle transport regulators play crucial roles in the mediation of cancer cell biology, including uncontrolled cell growth, invasion, and metastasis. The Rabs, like other members of the Ras superfamily, function as molecular switches through changes in its guanine nucleotide-binding status between the active GTP-bound and inactive GDP-bound forms. In its active, GTP-bound form, Rabs could mediate vesicular transport by allowing transport carriers or vesicles to engage specific effectors such as motor proteins and tethering factors, as well as vesicle fusion with the engagement of soluble N-ethylmaleimide sensitive factor (NSF) [82] attachment receptor (SNARE)

[83, 84] proteins. Vesicle delivery and dynamics are critical for regulating cell behavior associated with cell migration/invasion and tumorigenesis. Cooperation between Rabs and effectors in mediating vesicle movement pathways has significant influences on tumor progression and malignancy. Therefore, it raises the possibility that targeting a particular trafficking system may provide a new approach to cancer treatment [85]. As shown in this study, celecoxib targeted proteins, i.e., RAB2A, RAB10, and RAB11B are notably involved in Rab protein signal transduction. As shown in Figure 4B, TPP-identified proteins are enriched in GDP binding, GTPase activity, and protein phosphatase inhibitor activity that change the GTPases and, as a result, involve in mechanisms associated with cancer. Therefore, it seems that studying the effect of celecoxib on cancer models by TPP provide more supporting evidence.

Neurodegenerative diseases are also assigned to TPP-identified targets of celecoxib as an anti-inflammatory drug. Recent studies demonstrated that neuronal inflammation is a vital trigger of neurological diseases [66], and it exacerbates disorders including Alzheimer 's -, Parkinsons - , Huntingtons diseases, as well as amyotrophic lateral sclerosis and multiple sclerosis [62-65]. In the present study, some of the mentioned neurodegenerative disorders were enriched based on phenotypic-based biological annotations, such as schizophrenia and depression. Twelve of 44 TPP-identified celecoxib targets are involved in Alzheimer's disease metabolism, suggesting a high possibility of celecoxib involvement in the mechanisms of this neurodegenerative disease. Notably, inflammation of the nervous system is observed in these disorders, and it is accompanied by an increase in inflammatory cytokines [86-88]. We also illustrated that celecoxib could be beneficial in treating the diseases mentioned above that are associated with inflammation by affecting the biosynthesis pathway of prostaglandins by the involvement of four identified proteins, i.e., DCTN1, PSIP1, BAX and AMPH.

Finally, we describe the importance of PTMs for the thermal stability of proteins. We show that multiple PTMs are involved in the protein thermostability. For example, acetylation, which significantly affects the life span of intracellular proteins by avoiding intracellular proteases degradation, is enriched in all TPP-identified proteins [89, 90]. Citrullination is the specific PTM identified in celecoxib treated sample (See Fig. 5). It is related to the change of arginine to citrulline, which strongly affects the structure and function of proteins in both physiological and pathological processes such as apoptosis, multiple sclerosis, and Alzheimer's disease [91-93]. Interestingly, an important diagnostic tool in the painful inflammatory disease such as Rheumatoid arthritis is to use anti-cyclic citrullinated peptide (anti-CCP) antibodies which detect citrullination levels of the patients and NSAIDs including Celecoxib are usually prescribed for those patients [94, 95]. Our findings highlight the role of citrullinated proteins as a target of Celecoxib.

Conclusion

Although phenotypic-based screens have become increasingly popular in drug discovery, the major challenge of this approach is the mechanistic deconvolution of the putative drug action during screening. The promising TPP approach has been introduced and expanded to tackle such challenges. In the present study, targets of celecoxib within rat hippocampus were characterized using TPP as a high throughput target discovery approach.

We show that celecoxib plays an effector role in several signaling pathways and biological processes, which can be linked to various diseases such as neurodegenerative disorders and cancer. Therefore, in addition to inhibiting COX2, we illustrate that celecoxib might modify also other pathways. Our findings support the pharmaceutical reports related to the repurposing of celecoxib for cancer and neurodegenerative disorders [96-98]. It seems that celecoxib is potentially beneficial for treating cancer by inhibiting SERCA and increasing the intracellular concentration of calcium, which causes ER stress along with cell death. Another proposed mechanism is affecting the trafficking system since transport regulators play essential roles in the mediation of cancer cell biology and especially circulating tumor cells. We found a significant effect of this medicine on proteins involved in the trafficking system of cells.

On the other hand, neuronal inflammation is a major culprit of neurodegenerative diseases, proteins of which

were significantly enriched in the present study. Inflammation in CNS starts by stimulation of astrocytes, and it continues with entering environmental immune cells to the brain. This process causes overproduction of cytokines, nitric oxide, active oxygen species, prostaglandins and eventually damage and cause death of neurons [36, 66, 68, 88]. Our findings support the idea of using celecoxib for neuronal inflammation due to the explored association of celecoxib targets and the inflammation.

To conclude, we identified several novelCelecoxib protein targets using TPP, which could be of interest in order to modify several pathways in CNS. Our findings provide new molecular evidence for celecoxib to be used as an add-on therapy in neurodegenerative disorders and cancer. However, more preclinical and paraclinical evidence is required to suggest the true drug repurposing potential of celecoxib.

Author contribution

EG and RK performed experiments, contributed to data analysis, interpretation and manuscript first-draft writing. AK, MS, KG and HR contributed to sampling, performing drug treatment and protein extraction. RS and MB contributed to do mass spectrometry analysis. ZT contributed to bioinformatic data gathering. HR, RS, MJ and JT also contributed to data interpretation and manuscript writing. MJ, RJ, JT and MB conceived and commenced the project and provided direction on study design and feedback on the final results.

Acknowledgement

The authors also acknowledge Dr. Rozbeh Jafari and Dr. Farnaz Barneh for helpful comments. This study was financially supported by the National Institute for Medical Research Development of Iran (NIMAD) (Elite Grants, Grant No.964580), Academy of Finland (No. 317680) and European Research Council (No. 716063).

Competing Interests' Statement

None

Supplementary files

Supplementary file 1: Whole soluble protein concentrations at a range of temperature and celecoxib concentrations. The horizontal axis represents temperature, and the vertical axis shows protein concentration. Each section is dedicated to a particular celecoxib concentration, DMSO-control, and water control. As demonstrated by increasing the temperature, we have a significant decrease in protein concentration.

Supplementary file 2: The distribution of the expression profile of Rab-2A, one of the TPP-identified protein targets, across the rat organs and body based on the TISSUES database.

References

1. Johnson, A.J., et al., *The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks.* Biochemical Journal, 2002. **366** (3): p. 831-837.

2. Schönthal, A., *Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy.* British journal of cancer, 2007. **97** (11): p. 1465-1468.

3. Marnett, L.J., et al., *Arachidonic acid oxygenation by COX-1 and COX-2 Mechanisms of catalysis and inhibition.* Journal of Biological Chemistry, 1999. **274** (33): p. 22903-22906.

4. Perazella, M.A. and K. Tray, *Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs.* The American journal of medicine, 2001. **111** (1): p. 64-67.

5. Yaksh, T.L., et al., *The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1.* Journal of Neuroscience, 2001.**21** (16): p. 5847-5853.

6. Smith, W.L., D.L. DeWitt, and R.M. Garavito, *Cyclooxygenases: structural, cellular, and molecular biology.* Annual review of biochemistry, 2000. **69** (1): p. 145-182.

7. Atukorala, I. and D.J. Hunter, *Valdecoxib : the rise and fall of a COX-2 inhibitor.* Expert Opin Pharmacother, 2013. **14** (8): p. 1077-86.

8. Rahme, E., et al., *Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.*Rheumatology (Oxford), 2007. **46** (2): p. 265-72.

9. Wongrakpanich, S., et al., *A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly.* Aging Dis, 2018. **9** (1): p. 143-150.

10. Onder, G., et al., *NSAID-Related Psychiatric Adverse Events.*Drugs, 2004. **64** (23): p. 2619-2627.

11. Jones, R., *Nonsteroidal anti-inflammatory drug prescribing: past, present, and future.* The American Journal of Medicine, 2001.**110** (1, Supplement 1): p. S4-S7.

12. Fond, G., et al., *Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review.* Acta Psychiatrica Scandinavica, 2014.**129** (3): p. 163-179.

13. Sams-Dodd, F., *Target-based drug discovery: is something wrong?* Drug discovery today, 2005. **10** (2): p. 139-147.

14. Schenone, M., et al., *Target identification and mechanism of action in chemical biology and drug discovery.* Nature chemical biology, 2013. **9** (4): p. 232.

15. Schmidt, C., *GSK/Sirtris compounds dogged by assay artifacts* . 2010, Nature Publishing Group.

16. Swinney, D., *Phenotypic vs. target-based drug discovery for first-in-class medicines.* Clinical Pharmacology & Therapeutics, 2013.**93** (4): p. 299-301.

17. Lomenick, B., et al., *Target identification using drug affinity responsive target stability (DARTS).* Current protocols in chemical biology, 2011. **3** (4): p. 163-180.

18. West, G.M., L. Tang, and M.C. Fitzgerald, *Thermodynamic analysis of protein stability and ligand binding using a chemical modification-and mass spectrometry-based strategy.* Analytical chemistry, 2008. **80** (11): p. 4175-4185.

19. Molina, D.M., et al., *Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay.* Science, 2013. **341** (6141): p. 84-87.

20. Savitski, M.M., et al., *Tracking cancer drugs in living cells by thermal profiling of the proteome.* Science, 2014.**346** (6205): p. 1255784.

21. Reckzeh, E.S., et al., *Target Engagement of Small Molecules: Thermal Profiling Approaches on Different Levels.* Methods Mol Biol, 2019. **1888** : p. 73-98.

22. Pace, C.N. and T. McGrath, *Substrate stabilization of lysozyme to thermal and guanidine hydrochloride denaturation.* Journal of Biological Chemistry, 1980. **255** (9): p. 3862-3865.

23. Vedadi, M., et al., *Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination.* Proceedings of the National Academy of Sciences, 2006. **103** (43): p. 15835-15840.

24. Jarzab, A., et al., *Meltome atlas—thermal proteome stability across the tree of life.* Nature Methods, 2020. **17** (5): p. 495-503.

25. Kurganov, B., E. Rafikova, and E. Dobrov, *Kinetics of thermal aggregation of tobacco mosaic virus coat protein.* Biochemistry (Moscow), 2002. **67** (5): p. 525-533.

26. Asial, I., et al., *Engineering protein thermostability using a generic activity-independent biophysical screen inside the cell.* Nature communications, 2013. **4** (1): p. 1-8.

27. Franken, H., et al., *Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry.* Nature protocols, 2015.**10** (10): p. 1567.

28. Reinhard, F.B., et al., *Thermal proteome profiling monitors ligand interactions with cellular membrane proteins.* Nature methods, 2015. **12** (12): p. 1129-1131.

29. Becher, I., et al., *Thermal profiling reveals phenylalanine hydroxylase as an off-target of panobinostat.* Nature chemical biology, 2016. **12** (11): p. 908-910.

30. Mateus, A., T.A. Maatta, and M.M. Savitski, *Thermal proteome profiling: unbiased assessment of protein state through heat-induced stability changes.* Proteome science, 2016. **15** (1): p. 13.

31. Tanoli, Z., et al., *Exploration of databases and methods supporting drug repurposing: a comprehensive survey.* Brief Bioinform, 2020.

32. Zagidullin, B., et al., *DrugComb: an integrative cancer drug combination data portal.* Nucleic Acids Research, 2019. **47** (W1): p. W43-W51.

33. Pei, H., et al., *Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer.* Journal of proteome research, 2007. **6** (7): p. 2495-2501.

34. Dembo, G., S.B. Park, and E.D. Kharasch, *Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans.*Anesthesiology-Hagerstown, 2005. **102** (2): p. 409-415.

35. Kang, K.B., et al., *Enhanced sensitivity of celecoxib in human glioblastoma cells: induction of DNA damage leading to p53-dependent G 1 cell cycle arrest and autophagy.* Molecular cancer, 2009. **8** (1): p. 66.

36. Wang, R., et al., *ẽλεϛοξιβ-ινδυϛεδ ινηιβιτιον οφ νευρογενεσις ιν φεταλ φρονταλ ϛορτεξ ις αττενυατεδ βψ ϛυρϛυμιν ια Ωντ/β-ϛατενιν πατηωαψ.* Life sciences, 2017. **185** : p. 95-102.

37. Paulson, S.K., et al., *Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption.* J Pharmacol Exp Ther, 2001. **297** (2): p. 638-45.

38. Jafari, R., et al., *The cellular thermal shift assay for evaluating drug target interactions in cells.* Nature protocols, 2014.**9** (9): p. 2100.

39. Wiśniewski, J.R., et al., *Universal sample preparation method for proteome analysis.* Nature methods, 2009. **6** (5): p. 359-362.

40. Scifo, E., et al., *Proteomic analysis of the palmitoyl protein thioesterase 1 interactome in SH-SY5Y human neuroblastoma cells.*Journal of proteomics, 2015. **123** : p. 42-53.

41. Chen, E.Y., et al., *Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool.* BMC bioinformatics, 2013.**14** : p. 128-128.

42. Piñero, J., et al., *DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants.*Nucleic acids research, 2016: p. gkw943.

43. Köhler, S., et al., *Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources.* Nucleic Acids Res, 2019.**47** (D1): p. D1018-d1027.

44. Eppig, J.T., et al., *Mouse Genome Informatics (MGI): resources for mining mouse genetic, genomic, and biological data in support of primary and translational research* , in *Systems Genetics* . 2017, Springer. p. 47-73.

45. Taliun, S.A.G., et al., *Exploring and visualizing large-scale genetic associations by using PheWeb.* Nature Genetics, 2020.**52** (6): p. 550-552.

46. Kutmon, M., et al., *WikiPathways: capturing the full diversity of pathway knowledge.* Nucleic acids research, 2016. **44** (D1): p. D488-D494.

47. Nickchi, P., M. Jafari, and S. Kalantari, *PEIMAN 1.0: Post-translational modification Enrichment, Integration and Matching ANalysis.* Database : the journal of biological databases and curation, 2015. **2015** : p. bav037-bav037.

48. Petsko, G.A. and D. Ringe, *Protein structure and function* . 2004: New Science Press.

49. Guo, M., Y. Xu, and M. Gruebele, *Temperature dependence of protein folding kinetics in living cells.* Proc Natl Acad Sci U S A, 2012. **109** (44): p. 17863-7.

50. Usman, M.G., et al., *Heat shock proteins: functions and response against heat stress in plants.* International Journal Of Scientific and T echnology Research, 2014. **3** (11): p. 204-218.

51. Wishart, D.S., et al., *DrugBank 5.0: a major update to the DrugBank database for 2018.* Nucleic acids research, 2018.**46** (D1): p. D1074-D1082.

52. Hecker, N., et al., *SuperTarget goes quantitative: update on drug-target interactions.* Nucleic acids research, 2012.**40** (Database issue): p. D1113-D1117.

53. Skuta, C., et al., *Probes & Drugs portal: an interactive, open data resource for chemical biology.* Nature methods, 2017.**14** (8): p. 759-760.

54. Bento, A.P., et al., *The ChEMBL bioactivity database: an update.* Nucleic Acids Research, 2013. **42** (D1): p. D1083-D1090.

55. Tanoli, Z., et al., *Drug Target Commons 2.0: a community platform for systematic analysis of drug-target interaction profiles.*Database : the journal of biological databases and curation, 2018.**2018** : p. 1-13.

56. Tang, J., et al., *Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions.* Cell Chem Biol, 2018. **25** (2): p. 224-229.e2.

57. Palasca, O., et al., *TISSUES 2.0: an integrative web resource on mammalian tissue expression.* Database, 2018. **2018** .

58. Luo, M.-L., et al., *The Rab2A GTPase promotes breast cancer stem cells and tumorigenesis via Erk signaling activation.* Cell reports, 2015. **11** (1): p. 111-124.

59. Jafari, M., et al., *Exploring biological processes involved in embryonic stem cell differentiation by analyzing proteomic data.*Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 2013.**1834** (6): p. 1063-1069.

60. ; Available from: https://clincalc.com/DrugStats/Drugs/Celecoxib.

61. Onder, G., et al., *NSAID-related psychiatric adverse events: who is at risk?* Drugs, 2004. **64** (23): p. 2619-27.

62. Akiyama, H., et al., *Inflammation and Alzheimer's disease.*Neurobiology of aging, 2000. **21** (3): p. 383-421.

63. Eikelenboom, P. and W. Van Gool, *Neuroinflammatory perspectives on the two faces of Alzheimer's disease.* Journal of Neural Transmission, 2004. **111** (3): p. 281-294.

64. Hirsch, E., et al., *The Role of dial Reaction and Inflammation in Parkinson's Disease.* DOCUMENTATION PAGE, 2003. **991** : p. 214-228.

65. McGeer, P.L. and E.G. McGeer, *Inflammation and neurodegeneration in Parkinson's disease.* Parkinsonism & related disorders, 2004. **10** : p. S3-S7.

66. Terzi, M., et al., *The use of non-steroidal anti-inflammatory drugs in neurological diseases.* Journal of chemical neuroanatomy, 2018.**87** : p. 12-24.

67. Goncalves, M.B., et al., *The COX-2 inhibitors, meloxicam and nimesulide, suppress neurogenesis in the adult mouse brain.* British journal of pharmacology, 2010. **159** (5): p. 1118-1125.

68. Nam, S.M., et al., *Comparison of pharmacological and genetic inhibition of cyclooxygenase-2: effects on adult neurogenesis in the hippocampal dentate gyrus.* Journal of veterinary science, 2015.**16** (3): p. 245-251.

69. Haas, A.K., et al., *Analysis of GTPase-activating proteins: Rab1 and Rab43 are key Rabs required to maintain a functional Golgi complex in human cells.* J Cell Sci, 2007. **120** (Pt 17): p. 2997-3010.

70. Gaudet, P., et al., *Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.* Brief Bioinform, 2011. **12** (5): p. 449-62.

71. Sugawara, T., F. Kano, and M. Murata, *Rab2A is a pivotal switch protein that promotes either secretion or ER-associated degradation of (pro) insulin in insulin-secreting cells.* Scientific reports, 2014. **4** (1): p. 1-14.

72. Masferrer, J.L., et al., *Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.* Cancer research, 2000.**60** (5): p. 1306-1311.

73. Dannenberg, A.J. and K. Subbaramaiah, *Targeting cyclooxygenase-2 in human neoplasia: rationale and promise.* Cancer cell, 2003. **4** (6): p. 431-436.

74. Koehne, C.-H. and R.N. Dubois. *COX-2 inhibition and colorectal cancer* . in *Seminars in oncology* . 2004. Elsevier.

75. Grosch, S., et al., *Cyclooxygenase-2 (COX-2)–independent anticarcinogenic effects of selective COX-2 inhibitors.* Journal of the National Cancer Institute, 2006. **98** (11): p. 736-747.

76. Kashfi, K. and B. Rigas, *Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention.*Biochemical pharmacology, 2005. **70** (7): p. 969-986.

77. Pyrko, P., et al., *Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2, 5-dimethyl-celecoxib, a non-coxib analogue of celecoxib.* Molecular cancer therapeutics, 2007. **6** (4): p. 1262-1275.

78. Tanaka, K.-i., et al., *Involvement of intracellular Ca2+ levels in nonsteroidal anti-inflammatory drug-induced apoptosis.*Journal of Biological Chemistry, 2005. **280** (35): p. 31059-31067.

79. Wang, J.-L., et al., *Effect of celecoxib on Ca2+ movement and cell proliferation in human osteoblasts.* Biochemical pharmacology, 2004. **67** (6): p. 1123-1130.

80. Kim, S.-H., et al., *GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells.* Carcinogenesis, 2007.**28** (1): p. 223-231.

81. Chia, W.J. and B.L. Tang, *Emerging roles for Rab family GTPases in human cancer.* Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 2009. **1795** (2): p. 110-116.

82. Zhao, C., J.T. Slevin, and S.W. Whiteheart, *Cellular functions of NSF: not just SNAPs and SNAREs.* FEBS letters, 2007.**581** (11): p. 2140-2149.

83. Ungermann, C. and D. Langosch, *Functions of SNAREs in intracellular membrane fusion and lipid bilayer mixing.* Journal of cell science, 2005. **118** (17): p. 3819-3828.

84. Hong, W., *SNAREs and traffic.* Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 2005. **1744** (2): p. 120-144.

85. Tzeng, H.-T. and Y.-C. Wang, *Rab-mediated vesicle trafficking in cancer.* Journal of biomedical science, 2016. **23** (1): p. 70.

86. Morales, I., et al., *Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches.* Which New Directions for Alzheimer's Disease, 2015.

87. Agius, L.M., *Neuroinflammation as the proximate cause of signature pathogenic pattern progression in amyotrophic lateral sclerosis, AIDS, and multiple sclerosis.* Pathology research international, 2012. **2012** .

88. Philips, T. and W. Robberecht, *Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease.* The Lancet Neurology, 2011. **10** (3): p. 253-263.

89. Zhou, Y., et al., *Lysine acetylation stabilizes SP2 protein in the silkworm Bombyx mori.* J Insect Physiol, 2016. **91-92** : p. 56-62.

90. Lahusen, T.J., et al., *BRCA1 function in the intra-S checkpoint is activated by acetylation via a pCAF/SIRT1 axis.* Oncogene, 2018. **37** (17): p. 2343-2350.

91. Gyorgy, B., et al., *Citrullination: a posttranslational modification in health and disease.* The international journal of biochemistry & cell biology, 2006. **38** (10): p. 1662-1677.

92. Acharya, N.K., et al., *Neuronal PAD4 expression and protein citrullination: possible role in production of autoantibodies associated with neurodegenerative disease.* J Autoimmun, 2012. **38** (4): p. 369-80.

93. Piran, M., et al., *Can We Assume the Gene Expression Profile as a Proxy for Signaling Network Activity?* Biomolecules, 2020.**10** (6).

94. Kwiatkowska, B., et al., *Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion.* Reumatologia, 2017.**55** (6): p. 290-297.

95. Gilliam, B.E., A.K. Chauhan, and T.L. Moore, *Evaluation of anti-citrullinated type II collagen and anti-citrullinated vimentin antibodies in patients with juvenile idiopathic arthritis.* Pediatr Rheumatol Online J, 2013. **11** (1): p. 31.

96. Goldstein, B.I., et al., *Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature.* J Clin Psychiatry, 2009.**70** (8): p. 1078-90.

97. Assefnia, S., et al., *Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies.*Oncotarget, 2014. **5** (6): p. 1458-74.

98. Chuang, H.C., et al., *COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro.* Mol Cancer, 2008. **7** : p. 38.